Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

More clinical data on protease inhibitors.

GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies - 1 Oct 1995

Smart T

Abstract excerpt

Clinical information from Abbott Laboratories, Merck, Hoffman-LaRoche, and Agouron is provided on the following protease inhibitors: ritonavir, indinavir sulfate (Crixivan), saquinavir, and Viracept. Overall, the research presented suggests that higher doses of these drugs, and combinations with nucleoside analogs, appear to produce more potent and durable antiviral effects than seen in earlier protease inhibitor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Microbial
Share to HIV
Share to HIV Protease Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Patient Compliance

Share to Clinical Trials as Topic

Share to Acquired Immunodeficiency Syndrome

Share to CD4 Lymphocyte Count

Source

Identifiers

PMID: 11362917

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

More clinical data on protease inhibitors.PMID 11362917Read ↗

Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons.Semantic proximity Read ↗

Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials.Semantic proximity Read ↗

Current and Novel Inhibitors of HIV ProteaseSemantic proximity Read ↗

Simeprevir for the treatment of chronic hepatitis C.Semantic proximity Read ↗

Protease inhibitors for treatment of genotype 1 hepatitis C virus infection.Semantic proximity Read ↗

Recent developments in HIV protease inhibitor therapy.Semantic proximity Read ↗

New antiretroviral drugs part I: PIs.Semantic proximity Read ↗

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions.Semantic proximity Read ↗

Protease inhibitor-sparing regimens: new evidence strengthens position.Semantic proximity Read ↗

Emerging reverse transcriptase inhibitors for HIV-1 infectionSemantic proximity Read ↗

New drugs-reports of new drugs recently approved by the FDA. Abacavir sulfate.Semantic proximity Read ↗

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In VitroSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.